We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the experimental drug PR022 had failed to meet its primary endpoint in people with atopic dermatitis.
Realm Therapeutics, Inc., based in Malvern, Pennsylvania, announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis